Adipose-derived Stem Cells, Excimer Light, Stable Vitiligo
Conditions
Brief summary
This study aimed to assess the efficacy and safety of intradermal injection of adipose-derived stem cells, alone and combined with excimer light in treatment of stable vitiligo.
Detailed description
Vitiligo is a common disfiguring autoimmune disease that negatively affects patients' self-esteem and quality of life. Vitiligo is caused by a dynamic interplay between genetic and environmental risks that initiates an autoimmune attack on melanocytes in the skin. Adipose tissue-derived stem cells have the capacity to secrete a variable cytokines and growth factors, including hepatocyte growth factor (HGF), interleukin-6 (IL-6), macrophage colony-stimulating factor (M-CSF), transforming growth factor-β1 (TGF-β1), tumour necrosis factor (TNF), vascular endothelial growth factor (VEGF), that stimulate angiogenesis, tissue remodeling, and anti-apoptotic processes. Phototherapy has an eminent effect on stoppage of progression and repigmentaion of vitiligo patches. Narrowband ultraviolet B (NB-UVB) and ultraviolet A (UVA), and monochromatic excimer light (MEL) can be used in treatment of vitiligo. The specific 308-nm radiation wavelength is delivered in a targeted form by the xenon-chloride excimer laser and is also available in an incoherent form that is commonly referred to as the excimer lamp.
Interventions
PROCEDUREAdipose-derived Stem Cells Combined With Excimer Light
All patients received adipose-derived stem cells combined with excimer light.
Sponsors
Tanta University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
15 Years to 52 Years
Healthy volunteers
No
Inclusion criteria
* Patients with two or more similar patches of stable vitiligo "absence of new patches of depigmentation or enlargement of the pre-existing patches" for 6 months at least. * Patients who will accept to be enrolled in the study and will sign an informed consent.
Exclusion criteria
* Unstable vitiligo for more than 6 months. * Current bacterial or viral infection in the treatment area. * Patients with unrealistic expectation. * Very thin patients "poor donor areas". * Patients with uncontrolled systemic disease such as diabetes or hypertension. * Patients with hepatitis B or C virus infection. * Patients with any other skin disease. * Patients with bleeding or coagulopathy disorders. * Pregnancy and lactation. * Patients who received topical treatment for vitiligo during the last month, or systemic treatment during the past three months before the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Vitiligo Disease Activity (VIDA) Score | 6 months post-procedure | The Vitiligo Disease Activity (VIDA) Score is a 6-point clinical scale used to measure the progression or stability of vitiligo. The scale ranges from -1 to +4, where higher numbers indicate more recent and rapid disease activity: * 4: Active disease (new lesions or expansion) within the last 6 weeks. * 3: Active disease between 6 weeks and 3 months. * 2: Active disease between 3 and 6 months. * 1: Active disease between 6 and 12 months. 0: Stable disease with no changes for 1 year or longer. * 1: Stable for 1 year or longer, showing signs of spontaneous repigmentation |
Countries
Egypt
Outcome results
None listed